Compare AGEN & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | ASLE |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.8M | 309.5M |
| IPO Year | 1999 | 2018 |
| Metric | AGEN | ASLE |
|---|---|---|
| Price | $7.85 | $5.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.50 | $7.00 |
| AVG Volume (30 Days) | ★ 873.0K | 425.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 63.64 |
| EPS | ★ 0.96 | N/A |
| Revenue | $42,877,086.00 | ★ $335,286,000.00 |
| Revenue This Year | $107.63 | $23.41 |
| Revenue Next Year | N/A | $6.80 |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $5.27 |
| 52 Week High | $8.85 | $8.58 |
| Indicator | AGEN | ASLE |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 46.83 |
| Support Level | $2.97 | $5.34 |
| Resistance Level | $8.64 | $5.90 |
| Average True Range (ATR) | 0.43 | 0.15 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 54.07 | 48.33 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.